Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Только для подписчиков

Менопаузальная гормонотерапия и онкологические риски органов репродуктивной системы. Обзор литературы

https://doi.org/10.33667/2078-5631-2019-1-1(376)-42-50

Полный текст:

Аннотация

Представлены данные о рисках развития онкологических заболеваний органов репродуктивной системы у женщин в период менопаузального перехода и постменопаузе при лечении менопаузальных расстройств препаратами, предназначенными для менопаузальной гормонотерапии, содержащими различные дозы эстрогенов и прогестогенов, используемые в циклическом или непрерывном режиме.

Об авторе

Я. З. Зайдиева
ГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии»
Россия


Список литературы

1. Furness S., Roberts H., Marjoribanks J., Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst. Rev. Art. 2012; 8DOI: dx.doi.org/10,1002/14651858. CD 000402.pub4.

2. Roberts, H., Hickey, M., Lethaby, A.A. Cochrane review summary. Maturitas. 2014; 77:4-6.

3. Soules, M.R., Sherman, S., Parrott, E. Executive summary: Stages of Reproductive Ageing Workshop (STRAW). FertilSteril. 2001; 76: 874-878.

4. Writing. Group for the PEPI trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. J Am Med Assoc. 1996; 275: 370-375.

5. Politi M.C., Schleinitz M. D., Col, N.F. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Inter Med. 2008; 23: 1507-1513.

6. Peeyananjarassri K., Baber R. Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomised clinical trials. Climacteric. 2005; 8: 13-23.

7. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015; Feb 12. Epub ahead of print.

8. Beral V., Reeves G., Green J., Bull D. for the Million Women Study Collaborators. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007; 369: 1703-10.

9. The 2012 Hormone therapy position statement of: The North American Menopause Society. Menopause. 2012 Mar; 19 (3): 257-71.

10. IMS recommendations. Panay N., Hamoda H., Arya R., Savvas M. Menopause Int. 2013; 19 (2), 59-68.

11. Davis S. R., Baber R. J. Nature Reviews, Endocrinology; 2015 advanced on line publication.

12. de Villiers T.J, A. Pines, N. Panay, M. Gambacciani, D. F. Archer, R. J. Baber, S. R. Davis, A.A. Gompel, V. W. Henderson, R. Langer, R. A. Lobo, G. Plu-Bureau, D. W. Sturdee. Update 2013 IMS recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013; 16: 316-337.

13. de Villiers T. J., Gass M. L.S., Haines C. J., Hall J. E., Lobo R. A., Pierroz D. D., Rees M. Global Consensus Statement on Menopausal Hormone Therapy. Climacteric. 2013; 16: 203-204.

14. Менопаузальная гормонотерапия и сохранение здоровья женщин зрелого возраста Клинические рекомендации: протоколы. Под ред. Сухих Г. Т., Сметник В. П. М., 2015, 49 с.

15. International Agency for Research on Cancer. Working Group on the Evaluation of Carcinogenic Risks to Humans. Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. IARC Monogr Eval Carcinog Risks Hum 2007; 91: 1-528.

16. Burchell A. N., Winer R. L., de Sanjose S., Franco E. L. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine, 2006; 24: 52-61.

17. Yasmeen S., Romano P. S., Pettinger M., Johnson S. R., Hubbell F. A., Lane D. S., Hendrix S. L. Incidence of Cervical cytological abnormalities with aging in the women’s health initiative. Obstet Gynecol 2006; 108:410-9.

18. Parazzini F., La Vecchia C., Negri E., Franceschi S., Moroni S., Chatenoud L., Bolis G. Case-control study of oestrogen replacement therapy and risk of cervical cancer. BMJ 1997; 315: 85-8.

19. Smith E. M., Levy B.T., Rittchie J.M., Jia J., Wang D., Haugen T. H., Turek L. P. Is use of hormone replacement therapy associated with increased detection of human papillomavirus and potential risk of HPV-related genital cancers? European Journal of Cancer Prevention 2002; 11:295-305.

20. Sawaya G. F., Grady D., Kerlikwske K., La Valleur J., Barnabei V. M., Bass K., Snyder T. E., Picar J. H., Agarwal S. K., Mandelblatt J. The positive predictive value of cervical smears in previously screened postmenopausal women: The heart and estrogen/progestagen replacement study (HERS). Ann Intern Med 2000; 133: 942-50.

21. Lacey J. V. Jr, Brinton L. A., Barnes W. A., Gravitt P. E., Greenberg M. D., Hadjimichael O. C., McGowan L., Mortel R., Schwartz P.E., Kurman R. J., Hildesheim A. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol 2000; 77: 129-54.

22. Dahlstrom L.A., Ylitalo N., Sundstrom K., Palmgren J., Ploner A., Eloranta S., Sanjeevi C. B., Andersson S., Rohan T., Dillner J., Adami H-O., Sparen P. Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer2010; 127: 1923-30.

23. Baber R.J., Panay N., Fenton A., de Villiers T. J., Davis S. R., Pines A., Gompel A. A. Рекомендации IMS2016 г. по здоровью женщин зрелого возраста и менопаузальной гормональной терапии. Climacteric, 2016; 19: 2, 109-150.

24. www.cancer research.org/cancer-info/cer-vix/incidence (section reviewed 11(06/2014).

25. Marsden J., Sturdee D. Cancer issues. Best Pract Res Clin Obstet Gynaecol, 2009; 23: 87-107.

26. Jaakkola S., Pukkala E., Lyytinen H. K., Ylikorkala O. Postmenopausal estradiol-progestagen therapy and risk for uterine cervical cancer. Int J Cancer. 2012; 131: E 537-43.

27. Marino JL, McNamara HC, Hickey M. Managing menopausal symptoms after cancer: an evidence-based approach for primary care. Med J Aust2018; 208: 127-32.

28. Menopause Update, Endocr Pract. 2017; 23 (No. 7) 875.

29. Menopause: The Journal of The North American Menopause Society.2017. Vol. 24, No. 7, pp. 728-753.

30. Streuli I., Gaitzsch H., Wenger J-M., Petignat P. Endometriosis after menopause: physiopathology and management of an uncommon condition Climacteric, 2017, vol. 20; 2; 138-143.

31. Jaakkola S, Lyytinen HK, Dyba T, Ylikorkala O, Pukkala E. Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case-control study. International Journal of Cancer 2011; 128: 1644-51.

32. Jaakkola S, Lyytinen HK, Pukkala E, Ylikorkala O. Use of estradiol-progestin therapy associates with increased risk for uterine sarcomas. Gynecologic Oncology 2011; 122: 260-3.

33. Archer DF, Hendrix S, Ferentczy A, Gallagher JC, Rymer J, Skouby SO, den Hollander W, Stathopoulos V, Helmond FA, for the THEBES study group. Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women. Fertil Steril 2007; 4: 866-78.

34. Ettinger B, Kenemans P, Johnson SR, Mol-Arts M, Van Os S, Seifert W, Verweij PJ, Cummings SR. Endometrial effects of tibolone in elderly, osteoporotic women. Obstet Gynecol2008; 112: 653-9.

35. Langer RD, Landgren BM, Rymer J, Helmond FA. Effects of tibolone and continuous combined conjugated equine estragen/ medroxy progestesrone acetate on the endomterium and vaginal bleeding: results of the OPAL study. Am J Obstet Gynecol 2006; 195: 1320-7.

36. Beral V, Bull D, Reeves G, Million Women Study C. Endometrial cancer and hormone replacement therapy in the million women study. Lancet2005; 365: 1543-51.

37. Allen N., Tsilidis K., Key T., et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am.J. Epidemiol. 2010; 172: 1394-403.

38. Allen N., Tsilidis K., Key T., et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am.J. Epidemiol. 2010; 172: 1394-403.

39. Gompel A. Progesterone, progestins and the endometrium in perimenopause and in-menopausal hormone therapy. Climacteric. 2018 Aug.; 21 (4): 321-325.

40. Shim S. H., Lee S. J., Kim S. N. (2014)/Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. Eur. J. Cancer 50 (9): 1628-1637.

41. Deli T., Orosz M., Jakab A. Hormone Replacement Therapy in Cancer Survivors - Review of the Literature. Pathol. Oncol. Res. 2019. Jan 8.

42. Franke H. R., Vermes I. Differential effects of progestogens on breast cancer cell lines. Maturitas. 2003. Dec. 10; 46 Suppl.1: S55-8.

43. Fournier A. et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res. Treat. 2008; 107: 103-11

44. Lyytinen H., Pukkala E., Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet. Gynecol. 2009; 113: 65-73

45. Schneider C., Jick S. S., Meier C. R. Risk of gynecological cancers in users of estradiol/ dydrogesterone or other HRT preparations. Climacteric. 2009 Dec; 12 (6): 514-24.

46. Christine E, Lokkegaard L., Steinrud Morch L. Tibolone and risk of gynecological hormone sensitive cancer. Int. J. Cancer: 2018;142, 2435-2440.


Для цитирования:


Зайдиева Я.З. Менопаузальная гормонотерапия и онкологические риски органов репродуктивной системы. Обзор литературы. Медицинский алфавит. 2019;1(1):42-50. https://doi.org/10.33667/2078-5631-2019-1-1(376)-42-50

For citation:


Zaydieva Y.Z. Menopausal hormone therapy and cancer risks of reproductive system. Literature review. Medical alphabet. 2019;1(1):42-50. (In Russ.) https://doi.org/10.33667/2078-5631-2019-1-1(376)-42-50

Просмотров: 127


ISSN 2078-5631 (Print)